A phase II study on the role of gemcitabine plus romidepsin (GEMRO regimen) in the treatment of relapsed/refractory peripheral T-cell lymphoma patients.
about
Gemcitabine, dexamethasone, and cisplatin (GDP) as salvage chemotherapy for patients with relapsed or refractory peripheral T cell lymphoma-not otherwise specified.The discovery and development of romidepsin for the treatment of T-cell lymphoma.Treatment approaches of hard-to-treat non-Hodgkin lymphomas.Recent advances in understanding and managing T-cell lymphoma.Global analysis of histone lysine acetylation and proteomic changes in EC109 cells treated with the histone deacetylase inhibitor FK228.
P2860
A phase II study on the role of gemcitabine plus romidepsin (GEMRO regimen) in the treatment of relapsed/refractory peripheral T-cell lymphoma patients.
description
2016 nî lūn-bûn
@nan
2016 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2016 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
name
A phase II study on the role o ...... eral T-cell lymphoma patients.
@ast
A phase II study on the role o ...... eral T-cell lymphoma patients.
@en
type
label
A phase II study on the role o ...... eral T-cell lymphoma patients.
@ast
A phase II study on the role o ...... eral T-cell lymphoma patients.
@en
prefLabel
A phase II study on the role o ...... eral T-cell lymphoma patients.
@ast
A phase II study on the role o ...... eral T-cell lymphoma patients.
@en
P2093
P2860
P50
P1476
A phase II study on the role o ...... eral T-cell lymphoma patients.
@en
P2093
Cinzia Pellegrini
Debora Degl'Innocenti
Federico Monaco
Flavia Salvi
Italian Lymphoma Foundation (Fondazione Italiana Linfomi Onlus, FIL)
P2860
P2888
P356
10.1186/S13045-016-0266-1
P577
2016-04-12T00:00:00Z
P6179
1036688790